AstraZeneca's breast cancer pill camizestrant faces FDA delay for more data after advisory panel voted against its use with a CDK4/6 inhibitor. The company submitted longer-term efficacy results to support approval.
FDA delays AstraZeneca breast cancer pill decision
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →